PPD to Present at World Vaccine Congress 2011

WILMINGTON, N.C., (April 11, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced that several of its experts -- Lee Babiss, Ph.D., executive vice president of global laboratory services, Henrietta Ukwu, M.D., senior vice president of global regulatory services, and John Barry, vice president of alliance and sales management -- will speak at the 11th annual World Vaccine Congress 2011 Conference in Washington, D.C., on April 11-14.

Dr. Babiss will discuss innovation in research and development for large pharmaceutical companies in his plenary presentation, titled, "Paradigm Shift for Big Pharma: The Future Outlook for Innovation." He will highlight new models in emerging research and development and future investment strategies to fill the gap and sustain innovation. Dr. Babiss provides strategic direction and scientific leadership to PPD's bioanalytical, cGMP and global central laboratories, Phase I clinic, vaccines and biologics operations and to BioDuro. His presentation is Tuesday, April 12, at 9:10 a.m. ET.

Dr. Ukwu will highlight the innovative approaches to advancing vaccine development in her presentation, titled, "Strategic Transformation of the Vaccine Industry." She will address the regulatory environment for vaccines, and discuss the impact of commercialization and the value of vaccines in health care. Dr. Ukwu has global responsibility for regulatory services across all PPD lines of business and provides clinical vaccine expertise to advance the company's vaccines and biologics operations. Her presentation is Monday, April 11, at 2:25 p.m. ET.

Mr. Barry will discuss how contract research organizations (CROs) elicit effective external alliances and nontraditional partnership models in the vaccine industry and key factors central to capturing value and contributing to partnership success through CROs. His presentation, "Utilizing Outsourced Capabilities to Enhance and Speed Development Toward Licensure of Vaccines," will highlight how these alliances are structured to mitigate risk while delivering value and results to clients. Mr. Barry is a key leader in global business development, having held positions of increasing responsibility during his 20-year industry tenure. His presentation is Wednesday, April 13, at 5:25 p.m. ET.

The World Vaccine Congress conference is the largest vaccine industry event in North America, providing a forum to explore an area expected to reach $34 billion in revenue by 2012. Participants can visit PPD at Booth #20 to learn more about the company's vaccine service and expertise, including its Vaccines & Biologics Center of Excellence, a first-in-kind comprehensive network of integrated, world-class laboratory services focused specifically on vaccine and biologic drug development.

PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the information presented during these presentations are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; risks associated with and dependence on collaborative relationships; competition within the outsourcing industry; success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; rapid technological advances that make our products and services less competitive; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts
Media:
Sue Ann Pentecost
+1 919 456 5890
sueann.pentecost@ppdi.com

Analysts/Investors:
Luke Heagle
+1 910 558 7585
luke.heagle@ppdi.com